News articles about Stryker (NYSE:SYK) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm rates the sentiment of news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Stryker earned a daily sentiment score of 0.18 on Accern’s scale. Accern also gave news headlines about the medical technology company an impact score of 45.8005270502733 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the news stories that may have impacted Accern’s scoring:
- Analysts assigned mean rating score of 2.10 for Stryker Corporation (SYK) – Wall Street Morning (wallstreetmorning.com)
- The Law Offices of Vincent Wong Notifies Investors of an Investigation of Entellus Medical, Inc. Concerning the Sale … – Business Wire (press release) (businesswire.com)
- Stryker Corp. – Value Analysis (NYSE:SYK) : December 13, 2017 (finance.yahoo.com)
- Stryker (SYK) Reports Retirement of Howard Cox Jr. from Board – StreetInsider.com (streetinsider.com)
- Stryker Corporation’s (SYK) Superior Earnings Growth Keep it a Buy – Investorplace.com (investorplace.com)
A number of research firms recently commented on SYK. BMO Capital Markets raised shares of Stryker to a “market perform” rating and set a $163.00 price objective on the stock in a report on Tuesday. Needham & Company LLC reaffirmed a “hold” rating on shares of Stryker in a report on Thursday, December 7th. ValuEngine downgraded shares of Stryker from a “buy” rating to a “hold” rating in a report on Friday, December 1st. Robert W. Baird raised shares of Stryker from a “neutral” rating to an “outperform” rating in a research report on Friday, November 24th. Finally, SunTrust Banks reaffirmed a “buy” rating and set a $161.00 price target on shares of Stryker in a research report on Friday, November 17th. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating and thirteen have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $153.19.
Shares of Stryker (NYSE:SYK) traded down $1.97 during trading on Friday, hitting $151.34. 1,406,700 shares of the stock traded hands, compared to its average volume of 1,178,710. Stryker has a twelve month low of $116.50 and a twelve month high of $160.62. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.61 and a current ratio of 2.37. The firm has a market capitalization of $57,374.37, a P/E ratio of 24.30, a price-to-earnings-growth ratio of 2.41 and a beta of 0.78.
Stryker (NYSE:SYK) last issued its earnings results on Thursday, October 26th. The medical technology company reported $1.52 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.50 by $0.02. Stryker had a net margin of 14.67% and a return on equity of 24.11%. The company had revenue of $3.01 billion for the quarter, compared to the consensus estimate of $2.97 billion. During the same quarter in the previous year, the company earned $1.39 EPS. The firm’s revenue for the quarter was up 6.1% compared to the same quarter last year. analysts anticipate that Stryker will post 6.47 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 31st. Shareholders of record on Friday, December 29th will be issued a dividend of $0.47 per share. This is a boost from Stryker’s previous quarterly dividend of $0.43. This represents a $1.88 annualized dividend and a yield of 1.24%. The ex-dividend date of this dividend is Thursday, December 28th. Stryker’s payout ratio is currently 36.32%.
In other news, insider Lonny J. Carpenter sold 5,000 shares of the business’s stock in a transaction dated Friday, November 3rd. The stock was sold at an average price of $155.34, for a total transaction of $776,700.00. Following the completion of the transaction, the insider now directly owns 83,207 shares in the company, valued at approximately $12,925,375.38. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 7.40% of the company’s stock.
WARNING: This piece was first reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.thelincolnianonline.com/2017/12/15/stryker-syk-earning-somewhat-positive-news-coverage-study-finds.html.
Stryker Company Profile
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.